Study Supports Development Potential in Several Therapeutic Areas
Zengen, Inc. announced today that its researchers have discovered that activation of melanocortin receptors (MCR) subtypes MC1R and MC3R could be a novel strategy to control inflammatory disorders.
The findings, "Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation," appear in the March 2004 issue of Pharmacological Reviews, a publication of the American Society for Pharmacology and Experimental Therapeutics (ASPET).
"MCR activation causes a collective reduction of the major molecules involved in the inflammatory process," said Anna Catania, M.D., professor of endocrinology, School of Internal Medicine, University of Milan and lead author of the study. "This discovery is significant because it shows that treatment with melanocortin peptides doesnt abolish the inflammatory response but instead modulates it. An advantage of melanocortins in the treatment of inflammation is that their influences are broad and are not restricted to a specific mediator or chemical pathway."
Recognition and cloning of five melanocortin receptors has greatly improved understanding of peptide-target cell interactions. Preclinical investigations indicate that activation of certain MCR subtypes, primarily MC1R and MC3R, could be useful in treatment of localized and systemic inflammatory disorders. These include: organ transplantation, chronic inflammatory diseases, acute inflammation, inflammation within the brain and neurogenerative disorders, peripheral neuropathies, systemic host reactions, ischemia and reperfusion injury and infections.
"The study results also indicate that certain melanocortin peptides have antimicrobial effects," said James Lipton, Ph.D., chief scientific officer and director of Zengen and study author. "Unlike corticosteroids, melanocortins do not reduce microbial killing activity, but enhance it. We are encouraged by these findings and will continue our research and development efforts in peptide technology."
Zengens researchers also conducted a separate study on melanocortin receptors that was published in the February 2004 issue of the Journal of Leukocyte Biology. The study, titled, "Autocrine inhibitory influences of alpha-melanocyte-stimulating hormone in malignant pleural mesothelioma," showed that activation of express melanocortin 1 receptor (MC1R) by selective peptides or peptidomimetics might provide a novel strategy to reduce mesothelioma cell proliferation by taking advantage of an endogenous inhibitory circuit based on alpha-Melanocyte-Stimulating Hormone ((-MSH), and its receptor MC1R.
About Zengen, Inc.
Founded in 1999, Zengen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent infection and inflammation through application of its proprietary peptide technologies. Zengen is currently conducting Phase I/II clinical trials for CZEN 002, one of the Companys proprietary peptide molecules, for the treatment of vulvovaginal candidiasis, commonly known as vaginal yeast infection. For more information about Zengen, please visit www.zengen.com.
Kumiko Hakushi | Ruder Finn, Inc.
Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)
Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
22.06.2018 | Materials Sciences
22.06.2018 | Earth Sciences
22.06.2018 | Life Sciences